Quiros Juan Jose Chacon Sells 3,575 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total value of $214,786.00. Following the transaction, the director owned 1,220,004 shares of the company’s stock, valued at approximately $73,297,840.32. This represents a 0.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $55.31 on Monday. The firm’s 50-day moving average is $68.98 and its two-hundred day moving average is $62.21. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $83.31. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The stock has a market capitalization of $1.62 billion, a P/E ratio of -31.79 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the business earned ($1.19) earnings per share. On average, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in ESTA. Goldman Sachs Group Inc. increased its position in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares during the period. Viking Global Investors LP purchased a new position in Establishment Labs in the second quarter valued at $14,669,000. Bamco Inc. NY boosted its holdings in Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares during the period. Woodson Capital Management LP grew its stake in Establishment Labs by 113.3% during the 3rd quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after purchasing an additional 255,000 shares in the last quarter. Finally, Soleus Capital Management L.P. acquired a new position in Establishment Labs during the 2nd quarter worth $9,050,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ESTA has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their target price on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Citigroup decreased their target price on Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Finally, Needham & Company LLC raised their target price on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.